- | Tessera Therapeutics
BoB@JPM: Gene Writing With Tessera’s Michael Severino, M.D.
Flagship Pioneering plucked Michael Severino, M.D. away from AbbVie to run point at Tessera, a startup it’s backed to pioneer a new category of genetic medicine it calls gene writing.
- | Aphaia Pharma
Steffen-Sebastian Bolz, CSO of Aphaia Pharma Shares Insights from the P-II Study for Chronic Weight Management in Individuals with Obesity
Aphaia continues to create additional bead formulations to broaden its product portfolio to potentially enhance treatment efficacy for other metabolic diseases and patient populations in the future.
- | Ashvattha Therapeutics
First patient enrolled in phase 1/2 study of hydroxyl dendrimer imaging agent
Ashvattha Therapeutics announced that the first patient has been enrolled in a phase 1/2 study to evaluate the ability of an imaging agent to cross the blood-brain barrier and target key markers of neuroinflammation.
- | Xalud Therapeutics
To Health: Xalud Therapeutics Is Bringing Gene Therapy to the Masses
When the term “gene therapy” comes up, the first thing that comes to mind is often some sort of gene replacement or gene editing (either a DNA correction or disruption) to treat a well-defined Mendelian genetic disorder like sickle cell disease or phenylketonuria—not some broad, genetic, complex condition like inflammation or osteoarthritis. Well, unless you are Diem Nguyen, PhD, CEO of Xalud Therapeutics in New York City.
- | F2G
Valley Fever: What are the Signs and Symptoms
“Symptoms depend on the stage of disease and also which organs are affected,” said Dr. Emma Harvey, Global Head of Medical Affairs at the clinical-stage biopharmaceutical company F2G. “It starts as a respiratory disease and can be indistinguishable on symptoms from viral or bacterial pneumonia.”
- | Elixirgen Therapeutics
Using Self-Replicating RNA Technology to Treat Telomere Biology Disorders with Akihiro Ko Elixirgen Therapeutics
Akihiro Ko is the CEO and Co-Founder of Elixirgen Therapeutics, which was founded with the mission of treating patients using RNA technology. Their c-srRNA, controllable self-replicating RNA, technology is being applied to telomere biology disorders where patients have inherited short telomeres and a failure to develop bone marrow. Elixirgen is looking to restore the ability to create blood cells in patients suffering from this rare disease.
- | Canary Medical
Lessons from Serial CEOs in the Life Sciences
My biggest challenge was financing Canary. I think the concept behind Canary is timely, highly medically relevant, and an obvious next step in the evolution of medical devices—life-saving
- | F2G
4 issues infectious disease experts are focused on as fewer enter their profession
John Rex, MD, chief medical officer at drug discovery company F2G, told Becker’s he also feels the solution is two-part: legislative and research-driven.
